Impact on the carotid intima-medial thickness and safety of rosuvastatin in Chinese patients with carotid atherosclerosis: a meta-analysis
10.3760/cma.j.issn.0253-3758.2014.03.014
- VernacularTitle:瑞舒伐他汀对中国颈动脉粥样硬化患者内中膜厚度和安全性的荟萃分析
- Author:
Xueru FENG
1
;
Jingwei ZHANG
;
Meilin LIU
;
Xueying LI
Author Information
1. 100034,北京大学第一医院老年内科
- Keywords:
Atherosclerosis;
Carotid stenosis;
Treatment outcome;
Rosuvastatin
- From:
Chinese Journal of Cardiology
2014;42(3):247-253
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of rosuvastatin in Chinese patients with carotid atherosclerosis.Method A systematic search of Pubmed,EMBase,CENTRAL,CBMdisc,CNKI and WANFANG databases up to January 2013 was performed to identify studies comparing rosuvastatin with a placebo or other statins on carotid intima-medial thickness (IMT) with a minimum follow-up of 6 months in Chinese patients.Meta-analysis was performed by using RevMan 5.0 software after the strict evaluation of the methodological quality of the included studies independently by two reviewers.Results Twenty-eight studies involving 1 392 individuals were included in this review.The pooled weighted mean difference (WMD) between rosuvastatin and placebo or control on IMT was 0.28 mm (95％ CI 0.14-0.42,P ＜0.01),with 0.31 mm (95％CI0.14-0.49,P＜0.01) on6-8 months and0.16 mm (95％CI0.05-0.27,P=0.005) on 12 months,respectively.Analysis on studies in core journals showed the WMD between rosuvastatin and placebo or control on IMT was 0.18 mm (95％ CI 0.09-0.27,P ＜ 0.01).The WMD between rosuvastatin and other statins on IMT was 0.06 mm (95％ CI0.04-0.08,P ＜ 0.01).The WMD between rosuvastatin and placebo or control on plaque score was 0.89 (95％ CI 0.78-0.99,P ＜ 0.01).The WMD between rosuvastatin and placebo or control on plaque area was 1.46 (95％ CI 0.67-2.25,P ＜0.01).Reports of adverse effect were elevated liver enzyme (2.30％,19/825),elevated muscle enzyme (0.73％,6/825),muscle aches (0.61％,5/825).Conclusions Rosuvastatin therapy is effective and safe to decrease IMT in Chinese patients with carotid atherosclerosis.
